Media Inquiries

Contact:
Chris Wells
PMC
Phone: 202-580-9780


News

PMC Press Releases

« Back

PMC to Recognize Jay T. Flatley With 13th Annual Leadership in Personalized Medicine Award, Honoring Contributions in Science, Business, Policy


Flatley to share vision for future of personalized medicine at 13th Annual Personalized Medicine Conference


WASHINGTON (June 6, 2017)

 — 





In recognition of his contributions to the science, business and policy landscape for personalized medicine, the Personalized Medicine Coalition (PMC) will present the 13th Annual Leadership in Personalized Medicine Award to Jay T. Flatley, Executive Chairman, Illumina, at Harvard Medical School on November 15, 2017. 

Flatley is best known as a business leader. During his 17-year tenure as CEO of Illumina, Flatley oversaw the development of "next-generation sequencing” (NGS) instruments that helped establish a foundation for personalized medicine by driving the cost of sequencing a human genome down from around $10 million in 2006 to $1,000 today. Those efforts catalyzed an explosion in the generation of genomic data worldwide as the company’s sales increased from $1.3 million in 2000 to $2.2 billion in 2015. The resulting data support researchers and scientists’ ongoing efforts to understand which treatments work best for which patients. By enabling that research, many believe Flatley’s work has helped drive a paradigm shift that will forever change the way medicine is practiced. 

"Illumina’s technology has been essential to making personalized medicine a reality,” Michael Pellini, M.D., Chairman, Board of Directors, Foundation Medicine, who was one of three people who nominated Flatley for the award, said of Flatley’s contributions to the science underpinning the field.

Flatley has also played a leading role in shaping the policy landscape for personalized medicine. It was under his leadership in 2013 that the U.S. Food and Drug Administration (FDA) approved Illumina’s MiSeqDx ® NGS platform by measuring a subset of different types of genetic variants in multiple sequencing contexts, and the agency has cited that approach as a blueprint for its future work in NGS. Following the announcement of the agency’s decision regarding MiSeqDx, Francis Collins, M.D., Ph.D., Director, National Institutes of Health (NIH), and Margaret Hamburg, M.D., then Commissioner, FDA, heralded the approval’s larger significance for the field of medicine. 

"Access to these data opens the door for the transformation of research, clinical care and patient engagement,” they wrote in The New England Journal of Medicine

PMC will present the award to Flatley at 8:45 a.m. on the first day of the 13th Annual Personalized Medicine Conference. Registration for the conference is now open.


Contact:
Christopher J. Wells
cwells@personalizedmedicinecoalition.org
Phone: 202-589-1755

About the Personalized Medicine Coalition:
The Personalized Medicine Coalition, representing innovators, scientists, patients, providers and payers, promotes the understanding and adoption of personalized medicine concepts, services and products to benefit patients and the health system. For more information about PMC, please visit www.personalizedmedicinecoalition.org.

« Back

Join Today

PMC members shape and advance the future of personalized medicine.
» Sign Up Today



Talk to Us

To learn more about PMC membership, contact PMC Director of Membership & Development Mary Bordoni.